US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.2301
- +0.0021+0.92%
Close Nov 29 13:00 ET
- 0.2301
- 0.00000.00%
Post 16:54 ET
14.66MMarket Cap-489P/E (TTM)
0.2400High0.2230Low187.52KVolume0.2280Open0.2280Pre Close42.71KTurnover0.32%Turnover RatioLossP/E (Static)63.71MShares0.620052wk High5.00P/B13.35MFloat Cap0.162852wk Low--Dividend TTM58.02MShs Float836.0000Historical High--Div YieldTTM7.46%Amplitude0.1628Historical Low0.2270Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
AIM ImmunoTech Stock Forum
AIM ImmunoTech Refutes Activist Group's False and Misleading Claims
2 minutes ago, 12:30 PM PST
Via BusinessWire
Sets Record Straight on Mischaracterization of AIM's Historical Share Price
Reminds AIM Shareholders of Activist Group's Numerous Lies, Omissions and Misrepresentations in Multi-Year Effort to Take Control of the Board
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Receiv...
2 MINUTES AGO, 3:30 PM EST
VIA BUSINESSWIRE
Sets Record Straight on Mischaracterization of AIM's Historical Share Price
Reminds AIM Shareholders of Activist Group's Numerous Lies, Omissions and Misrepresentations in Multi-Year Effort to Take Control of the Board
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Received...
4 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data were published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's drug Ampligen® (also known as rintatolimod) ...
AIM ImmunoTech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(6.84%),Steven Boyd(6.84%)
4 mins ago
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
📊⚡️📊
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally wel...
No comment yet